Drug price negotiations will become an important means of entering health insurance.

Prior to this, some industry voices believed that the national drug price negotiation had a far greater impact on the reputation of pharmaceutical companies than on their substantive performance. However, according to the latest news, drug price negotiation may become an important means to enter the medical insurance catalogue in the future. Early entry into medicine will receive various policy support from the government, and those products that do not reduce prices may face many relevant policy restrictions, especially those products that were originally researched but have exceeded the patent protection period. The state may encourage looting. The form of imitation is contained.

According to the notice of seven ministries and commissions, including the State Health and Family Planning Commission, and the notice of the General Office of the Chongqing Health and Family Planning Commission on doing a good job in the centralized procurement of national drug price negotiations, the health and Family Planning Commission of all districts and counties (autonomous counties) in Chongqing, the Social Development Bureau of Liangjiang New area, the Health and Family Planning Bureau of Wansheng Economic Development District, and all subordinate medical institutions, the national drug price negotiation drugs used by the staff hospitals of large enterprises and institutions will not be included in the statistics of the proportion of drugs.

In terms of specific operations, the notice shows that, first, the country negotiates drug varieties and time periods that are not included in statistics and assessments. The first batch of negotiated drugs announced by the state include tenofovir disoproxil fumarate (300mg * 30 tablets/bottle), icotinib hydrochloride (125mg * 21 tablets/box) and gefitinib hydrochloride (250mg * 10 tablets/box) (see annex for negotiation results), and the procurement cycle is 2016-2017. During the procurement cycle, the Health Planning Commission temporarily implemented separate accounting for the drugs negotiated by the state, and the three drugs were not calculated when the medical institutions counted and filled in the proportion index.

In the promotion of medical reform, some medical reform goals will be put forward every year at the national level. One of the most important indicators for 2017 is: according to the "Guiding Opinions on the Pilot Comprehensive Reform of Urban Public Hospitals" issued by the General Office of the State Council, the proportion of drugs in public hospitals in pilot cities (excluding Chinese herbal pieces) will be reduced to about 30% by 2017. Another goal is to fully implement the comprehensive pilot reform of urban public hospitals in 2017, which means that all public hospitals across the country need to reduce the proportion of drugs to less than 30% in the shortest possible time.

This goal means that the market will be compressed on a large scale for pharmaceutical companies, but this time Chongqing's policy, that is, the policy of not including national drug price negotiation drugs in the drug share statistics, is undoubtedly After closing the door, another window has been opened, allowing those varieties that enter the drug price negotiation to fully release sales.

In the list of the first batch of drug price negotiations last year, tenofovir disoproxil for the treatment of hepatitis B and icotinib and gefitinib for the treatment of non-small cell lung cancer were included. At that time, it seemed that this was a price-for-quantity gamble for enterprises involved, and the docking with medical insurance was not very clear.

Immediately afterwards, that is, at the end of last year, of the 34 provinces in the country, only 14 provinces included national drug price negotiation drugs in the scope of various medical insurance reimbursements, and of these 14 provinces, only Xinjiang included them as a whole. Urban and rural medical insurance, other provinces only include the new rural cooperative or serious illness insurance. Under the cascade of various current situations, people in the industry sneer at the change of drug price negotiation, all think that it is difficult to land, and some people are even waiting to see the jokes of these enterprises.

However, after these two notices come out, the previous doubts will disappear, because from the national level, its support for the drug price negotiation mechanism is beyond doubt. In addition, the above-mentioned first batch of national drug price negotiation products also entered the medical insurance catalog at the beginning of this year. This support provides a strong guarantee for the rapid growth of these products for price-for-volume enterprises.

As a pioneer of medical reform in recent years, Chongqing has taken the lead in supporting drug price negotiations in the form of preferential policies, which allows national drug price negotiation products to be sold in Chongqing without restrictions, which is bound to usher in explosive product growth. This is undoubtedly a major blow to similar competing products. For example, gefitinib, the first generic drug of Qilu, which has just been approved, is likely to be excluded from the market because of the policy, because it is these three drugs that are not included in the proportion of drugs, not generic names. The news means that the sales of products from other related companies will become more difficult.

In addition, the Chongqing Health Planning Commission also has a foreshadowing: to strengthen policy propaganda and guidance. The content is that the results of the first three negotiated drugs announced by the state have all dropped significantly on the basis of the original price, and all of them are connected with medical insurance reimbursement, which significantly reduces the burden of medical expenses for patients, and is one of the measures to benefit the people of medical reform. All districts, counties and medical institutions should strengthen publicity and guidance, and smooth the national negotiation of drug procurement and use channels. According to sources, many of the government's drug price negotiations are urgently needed by the market, but manufacturers are unwilling to reduce prices, and local drugs cannot be imitated in a short time. The implementation of this strategy will not only reduce the burden on patients, but also allow pharmaceutical companies to get enough benefits. Therefore, from the national level, the work of drug price negotiation should not only be vigorously promoted, but also make the enterprises entering the drug price negotiation profitable. Therefore, the follow-up government will still provide various favorable guarantees to make the policy land.

The Ministry of Human Resources and Social Affairs announced on April 14 the 2017 version of the list of negotiated drugs for health insurance items, this time 44 varieties entered. From here, the state's support for drug price negotiations is already very obvious. Entering the catalog means that the market can be obtained. Presumably, the medical reform path of the Chongqing Health and Family Planning Commission will be followed by many other places.

I believe that in the next few years, for the imitation pharmaceutical industry, "grabbing imitation" will be the most effective way to occupy the market!

News source:http://www.y-lp.cn/pages/Article.aspx?id=5739735075886689644

This news was re-edited and reorganized by the Huaxun team and added analytical comments.